金城医药：克立硼罗获得化学原料药上市申请批准

Core Viewpoint - Jincheng Pharmaceutical's subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug, Clobetasol [1] Group 1: Company Information - Clobetasol is a phosphodiesterase 4 (PDE-4) inhibitor, indicated for topical treatment of mild to moderate atopic dermatitis in patients aged 3 months and older [1] - The company has 22 competitors in China with A registration status for Clobetasol raw materials [1] Group 2: Market Data - According to IMS data, the global sales figures for Clobetasol formulations are projected to be $224 million in 2022, $206 million in 2023, and $196 million in 2024 [1] - The consumption of Clobetasol raw materials is expected to be 706.68 kg in 2022, 963.57 kg in 2023, and 1118.43 kg in 2024 [1]